APA

Sutkowski D. M., Audia J. E., Goode R. L., Hsiao K. C., Leibovitch I. Y., McNulty A. M. & Neubauer B. L. (19960628). Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitor. : The Prostate. Supplement.

Chicago

Sutkowski D M, Audia J E, Goode R L, Hsiao K C, Leibovitch I Y, McNulty A M and Neubauer B L. 19960628. Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitor. : The Prostate. Supplement.

Harvard

Sutkowski D. M., Audia J. E., Goode R. L., Hsiao K. C., Leibovitch I. Y., McNulty A. M. and Neubauer B. L. (19960628). Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitor. : The Prostate. Supplement.

MLA

Sutkowski D M, Audia J E, Goode R L, Hsiao K C, Leibovitch I Y, McNulty A M and Neubauer B L. Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitor. : The Prostate. Supplement. 19960628.